{"id":3567,"date":"2024-08-02T15:05:51","date_gmt":"2024-08-02T15:05:51","guid":{"rendered":"https:\/\/longchangextracts.com\/?p=3567"},"modified":"2024-08-02T15:05:51","modified_gmt":"2024-08-02T15:05:51","slug":"bufei-huoxue-capsules","status":"publish","type":"post","link":"https:\/\/longchangextracts.com\/hu\/bufei-huoxue-capsules\/","title":{"rendered":"A Bufei Huoxue kapszula lehets\u00e9ges hat\u00e1smechanizmus\u00e1nak felt\u00e1r\u00e1sa a t\u00fcd\u0151fibr\u00f3zis kezel\u00e9s\u00e9ben a h\u00e1l\u00f3zati farmakol\u00f3gia alapj\u00e1n"},"content":{"rendered":"

A Bufei Huoxue kapszula lehets\u00e9ges hat\u00e1smechanizmus\u00e1nak felt\u00e1r\u00e1sa a t\u00fcd\u0151fibr\u00f3zis kezel\u00e9s\u00e9ben a h\u00e1l\u00f3zati farmakol\u00f3gia alapj\u00e1n<\/p>\n

A t\u00fcd\u0151fibr\u00f3zis (PF) kr\u00f3nikus, irreverzibilis interstiti\u00e1lis t\u00fcd\u0151betegs\u00e9g, amelyet a t\u00fcd\u0151 fibroblasztok myofibroblasztokk\u00e1 t\u00f6rt\u00e9n\u0151 aktiv\u00e1l\u00f3d\u00e1sa \u00e9s az extracellul\u00e1ris m\u00e1trix szekr\u00e9ci\u00f3ja jellemez. Ez a betegs\u00e9g k\u00fcl\u00f6nb\u00f6z\u0151 t\u00fcd\u0151betegs\u00e9gek v\u00e9gst\u00e1dium\u00fa megnyilv\u00e1nul\u00e1sa, ahol a norm\u00e1lis t\u00fcd\u0151sz\u00f6veti strukt\u00fara megbomlik, \u00e9s hely\u00e9t rendellenesen helyre\u00e1ll\u00edtott hegsz\u00f6vet veszi \u00e1t. A PF-nek k\u00fcl\u00f6nb\u00f6z\u0151 klinikai alt\u00edpusai vannak, amelyek progressz\u00edv rohamok form\u00e1j\u00e1ban jelentkeznek, amelyek k\u00f6z\u00fcl az idiop\u00e1ti\u00e1s PF a leggyakoribb t\u00edpus. A betegs\u00e9g oka jelenleg ismeretlen, t\u00fal\u00e9l\u00e9si ideje r\u00f6vid, \u00e9s nem \u00e1llnak rendelkez\u00e9sre specifikus kezel\u00e9si gy\u00f3gyszerek. A PF el\u0151fordul\u00e1si ar\u00e1nya \u00e9s mortalit\u00e1sa \u00e9vr\u0151l \u00e9vre n\u0151, k\u00fcl\u00f6n\u00f6sen a t\u00fcd\u0151interstitium k\u00fcl\u00f6nb\u00f6z\u0151 l\u00e9g\u00fati v\u00edrusok \u00e1ltali ism\u00e9telt fert\u0151z\u00e9se miatt, ami a betegs\u00e9get fiatalabb\u00e1 teszi. Jelenleg m\u00e9g mindig nagy tud\u00e1shi\u00e1ny van a betegs\u00e9ggel kapcsolatban a klinikumban. B\u00e1r k\u00e9t gy\u00f3gyszer, a pirfenidon \u00e9s a nintedanib sz\u00e9les k\u00f6rben elfogadott a klinikai gyakorlatban, klinikai hat\u00e9konys\u00e1guk nem kiel\u00e9g\u00edt\u0151.
\nA PF a hagyom\u00e1nyos k\u00ednai orvosl\u00e1s olyan betegs\u00e9geinek kateg\u00f3ri\u00e1j\u00e1ba tartozik, mint a \"t\u00fcd\u0151elz\u00e1r\u00f3d\u00e1s\" vagy a \"t\u00fcd\u0151impotencia\". A betegs\u00e9g kezdet\u00e9n a hosszan tart\u00f3 k\u00f6h\u00f6g\u00e9s hi\u00e1nyhoz vezet, amely f\u0151k\u00e9nt a qi hi\u00e1nya miatt \"t\u00fcd\u0151elz\u00e1r\u00f3d\u00e1sk\u00e9nt\" jelentkezik; A betegs\u00e9g tov\u00e1bb fejl\u0151dik, \u00e9s a k\u00e9s\u0151i szakaszban mind a qi, mind a jin hi\u00e1nya fenn\u00e1ll, ami t\u00fcd\u0151m\u0171k\u00f6d\u00e9si zavarokat eredm\u00e9nyez. A hossz\u00fa t\u00e1v\u00fa betegs\u00e9g k\u00f6h\u00f6g\u00e9shez \u00e9s zih\u00e1l\u00e1shoz vezet, ami kimer\u00edti a t\u00fcd\u0151 yinj\u00e9t \u00e9s t\u00fcd\u0151h\u0151m\u00e9rs\u00e9kletet okoz. Ez a yin folyad\u00e9k vissza\u00e1raml\u00e1s\u00e1t okozhatja, ami a t\u00fcd\u0151 kisz\u00e1rad\u00e1s\u00e1hoz \u00e9s kisz\u00e1rad\u00e1s\u00e1hoz, a t\u00e1pl\u00e1l\u00e9k elveszt\u00e9s\u00e9hez vezet, \u00e9s v\u00e9g\u00fcl a t\u00fcd\u0151 impotenci\u00e1j\u00e1hoz. Err\u0151l sz\u00f3l Su Wen \"Essz\u00e9 az impotenci\u00e1r\u00f3l\" c\u00edm\u0171 \u00edr\u00e1sa: \"Ha a t\u00fcd\u0151 forr\u00f3 \u00e9s a levelek megperzsel\u0151dnek,... akkor impotencia l\u00e9p fel\". Ezt a betegs\u00e9get el\u0151sz\u00f6r a qi hi\u00e1nya okozza, ami hasmen\u00e9shez, izzad\u00e1shoz \u00e9s a szerveket t\u00e1pl\u00e1l\u00f3 testnedvek hi\u00e1ny\u00e1hoz vezet. Ez\u00e9rt a klinikai gyakorlatban a t\u00fcd\u0151 t\u00e1pl\u00e1l\u00e1s\u00e1t \u00e9s a yin ter\u00e1pi\u00e1t haszn\u00e1lj\u00e1k a t\u00fcd\u0151impotencia kezel\u00e9s\u00e9re, mik\u00f6zben a qi-t is p\u00f3tolj\u00e1k. A t\u00fcd\u0151 a sz\u00e1z meridi\u00e1nnal szemben helyezkedik el, \u00e9s feladata a v\u00edz, a szemcs\u00e9k \u00e9s az esszencia sz\u00e1ll\u00edt\u00e1sa. Amikor a h\u0151 k\u00f3rokoz\u00f3k k\u00e1ros\u00edtj\u00e1k a t\u00fcd\u0151t \u00e9s a qi kimer\u00edti a yin-t, a sz\u00e1ll\u00edt\u00e1s megsz\u0171nik \u00e9s a szervek megvonj\u00e1k a t\u00e1pl\u00e1l\u00e9kot, ami impotencia-szindr\u00f3m\u00e1hoz vezet.
\nA Bufei Huoxue kapszula (BHC) Astragalus membranaceusb\u00f3l, Paeonia lactiflora-b\u00f3l \u00e9s Fructus Psorale-b\u00f3l kivont hat\u00f3anyagokb\u00f3l k\u00e9sz\u00fcl, \u00e9s a klinikai gyakorlatban sz\u00e9les k\u00f6rben alkalmazz\u00e1k t\u00fcd\u0151betegs\u00e9gek kezel\u00e9s\u00e9re. A Huangqi \u00e9des \u00e9s enyh\u00e9n meleg term\u00e9szet\u0171, amely k\u00e9pes szab\u00e1lyozni a l\u00e9p \u00e9s a t\u00fcd\u0151 meridi\u00e1nokat. A test t\u00e1pl\u00e1l\u00e1s\u00e1nak, a k\u00fcls\u0151 er\u0151s\u00edt\u00e9s\u00e9nek, valamint a l\u00e9p \u00e9s a k\u00f6z\u00e9ps\u0151 toniz\u00e1l\u00e1s\u00e1nak funkci\u00f3ja van; a v\u00f6r\u00f6s bazsar\u00f3zsa keser\u0171 \u00e9s enyh\u00e9n hideg term\u00e9szet\u0171, \u00e9s a m\u00e1j meridi\u00e1nj\u00e1hoz tartozik. H\u0151tiszt\u00edt\u00f3, v\u00e9rh\u0171t\u0151, a v\u00e9r pang\u00e1s\u00e1t eloszlat\u00f3 \u00e9s f\u00e1jdalomcsillap\u00edt\u00f3 hat\u00e1s\u00fa; a Psoralea meleg term\u00e9szet\u0171, a vese \u00e9s a l\u00e9p meridi\u00e1nokhoz t\u00e9r vissza. Funkci\u00f3i a qi szab\u00e1lyoz\u00e1s\u00e1ra, az asztma enyh\u00edt\u00e9s\u00e9re, a ves\u00e9k toniz\u00e1l\u00e1s\u00e1ra \u00e9s a yang er\u0151s\u00edt\u00e9s\u00e9re terjednek ki. A h\u00e1rom gy\u00f3gyszer egy\u00fcttesen t\u00e1pl\u00e1lja a t\u00fcd\u0151t, er\u0151s\u00edti a ves\u00e9ket, el\u0151seg\u00edti a v\u00e9rkering\u00e9st \u00e9s megsz\u00fcnteti a v\u00e9r pang\u00e1s\u00e1t. Ez a tanulm\u00e1ny a BHC PF-ellenes hat\u00e1s\u00e1nak lehets\u00e9ges mechanizmus\u00e1t a h\u00e1l\u00f3zati farmakol\u00f3giai m\u00f3dszerekkel j\u00f3solja meg, \u00e9s a h\u00e1l\u00f3zati farmakol\u00f3gia eredm\u00e9nyeit \u00e1llatk\u00eds\u00e9rleteken kereszt\u00fcl ellen\u0151rzi, gazdag\u00edtva a hagyom\u00e1nyos k\u00ednai orvosl\u00e1s PF megel\u0151z\u00e9s\u00e9nek \u00e9s kezel\u00e9s\u00e9nek elm\u00e9leti alapjait, \u00e9s kutat\u00e1si alapot biztos\u00edtva a BHC klinikai alkalmaz\u00e1s\u00e1hoz.<\/p>\n

Betegs\u00e9gk\u00e9nt a t\u00fcd\u0151 m\u0171k\u00f6d\u00e9si zavar\u00e1t a kr\u00f3nikus k\u00f6h\u00f6g\u00e9s \u00e9s zih\u00e1l\u00e1s, a t\u00fcd\u0151 qi-hi\u00e1ny, a szervek m\u0171k\u00f6d\u00e9si zavarai \u00e9s a t\u00fcd\u0151nek a test qi-j\u00e9t ir\u00e1ny\u00edt\u00f3 m\u0171k\u00f6d\u00e9se kell, hogy okozza. A v\u00e9rerek kering\u00e9se kedvez\u0151tlen, ami l\u00e9phi\u00e1nnyal \u00e9s t\u00falzott nedvess\u00e9ggel p\u00e1rosul, ami v\u00e9g\u00fcl v\u00e1lad\u00e9k-\u00f6sszefoly\u00e1shoz \u00e9s v\u00e9r pang\u00e1shoz vezet, ami viszont s\u00falyosb\u00edtja a t\u00fcd\u0151hi\u00e1ny szindr\u00f3m\u00e1j\u00e1t, \u00e9s \u00f6rd\u00f6gi k\u00f6rt alkot. Ez a PF klinikai progresszi\u00f3j\u00e1nak visszaford\u00edthatatlan TCM-patogenezise. A Qi-hi\u00e1ny a PF kialakul\u00e1s\u00e1nak kiv\u00e1lt\u00f3 t\u00e9nyez\u0151je, \u00e9s a betegs\u00e9g el\u0151rehaladt\u00e1val a betegs\u00e9g v\u00e9gs\u0151 st\u00e1dium\u00e1ban elker\u00fclhetetlen a pang\u00e1s. A Bels\u0151 K\u00e1non vil\u00e1gosan kimondja: \"Ha a v\u00e9r b\u0151s\u00e9ges, akkor azt kell meghat\u00e1rozni; ha a qi hi\u00e1nyos, akkor azt kell ellen\u0151rizni \u00e9s el\u0151id\u00e9zni.\". A BHC pontosan erre a m\u00f3dszerre \u00e9p\u00fcl, mint f\u0151 kezel\u00e9si m\u00f3dszerre \u00e9s a l\u00e1tens gy\u00f3gyszerformul\u00e1k kifejleszt\u00e9s\u00e9nek elm\u00e9leti alapj\u00e1ra.
\nA fenti tanulm\u00e1ny meg\u00e1llap\u00edtotta, hogy a BHC a TNF jel\u00e1tviteli \u00fatvonalba val\u00f3 beavatkoz\u00e1ssal a p38, az MMP9 \u00e9s a TNF - \u03b1 c\u00e9lpontokon kereszt\u00fcl gyakorolja a PF-ellenes funkci\u00f3t. A tumor nekr\u00f3zis faktort (TNF) az 1970-es \u00e9vekben fejlesztette ki E. A. Carswell \u00e9s kutat\u00f3csoportja felfedezte, hogy a mononukle\u00e1ris makrof\u00e1gok \u00e1ltal szintetiz\u00e1lt \u00e9s szekret\u00e1lt TNF-et 1958-ig nem hat\u00e1rozt\u00e1k meg specifikusan. Ezt k\u00f6vet\u0151en a tud\u00f3sok fokozatosan felfedezt\u00e9k, hogy m\u00e1s sejtek, k\u00f6zt\u00fck az NK-sejtek \u00e9s a T-limfocit\u00e1k is k\u00e9pesek TNF-et termelni. A kutat\u00e1sok kimutatt\u00e1k, hogy a TNF - \u03b1 szorosan r\u00e9szt vesz a helyi sz\u00f6vetek gyullad\u00e1sos v\u00e1lasz\u00e1ban, f\u0151k\u00e9nt az\u00e9rt, mert el\u0151seg\u00edtheti az NLRP3 testek \u00e1ltal k\u00e9pviselt gyullad\u00e1sos anyagok termel\u00e9s\u00e9t, a t\u00fcd\u0151 fibroblasztok aktiv\u00e1l\u00f3d\u00e1s\u00e1t \u00e9s az extracellul\u00e1ris m\u00e1trix szekr\u00e9ci\u00f3j\u00e1t. Ugyanakkor a TNF - \u03b1 s\u00falyosb\u00edthatja a gyullad\u00e1sos k\u00e1rosod\u00e1st is, ami abban nyilv\u00e1nul meg, hogy k\u00e9pes egyed\u00fcl vagy a komplement C3A \u00e9s C5A komplementtel egy\u00fctt hatni, citotoxikus hat\u00e1st kifejtve. \u00d6sszefoglalva, a TNF - \u03b1 d\u00f6nt\u0151 szerepet j\u00e1tszik a PF kialakul\u00e1s\u00e1ban \u00e9s fejl\u0151d\u00e9s\u00e9ben. Az MMP-k cinkf\u00fcgg\u0151 prote\u00e1zok, amelyek f\u0151 funkci\u00f3ja az ECM lebont\u00e1sa. Els\u0151, 1961-es felfedez\u00e9s\u00fck ut\u00e1n t\u00f6bb, ugyanabba a csal\u00e1dba tartoz\u00f3 prote\u00e1zt fedeztek fel. Norm\u00e1l k\u00f6r\u00fclm\u00e9nyek k\u00f6z\u00f6tt az MMP9 aktivit\u00e1sa nagyon alacsony. A feh\u00e9rje aktiv\u00e1l\u00e1sa ut\u00e1n els\u0151sorban az ECM lebont\u00e1s\u00e1\u00e9rt felel\u0151s. Meger\u0151s\u00edtett\u00e9k, hogy az MMP9 aktivit\u00e1sa jelent\u0151sen megn\u00f6vekedett a PF betegek t\u00fcd\u0151sz\u00f6vet\u00e9ben, \u00e9s a bronchoalveol\u00e1ris mos\u00f3folyad\u00e9kban is jelent\u0151sen megn\u00f6vekedett a tartalma. Ennek f\u0151 oka az ECM-szekr\u00e9ci\u00f3 k\u00e1ros hat\u00e1sainak adapt\u00edv kik\u00fcsz\u00f6b\u00f6l\u00e9se. Az elm\u00falt \u00e9vekben k\u00fcl\u00f6nb\u00f6z\u0151 biol\u00f3giai folyamatokat tal\u00e1ltak \u00f6sszef\u00fcgg\u00e9sbe hozhat\u00f3nak a PF betegs\u00e9g kialakul\u00e1s\u00e1val, amelyek k\u00f6z\u00fcl egyre nagyobb figyelmet kapott a p38 feh\u00e9rje, amely szorosan kapcsol\u00f3dik a sejt apopt\u00f3zishoz \u00e9s a sejtciklushoz. A II. t\u00edpus\u00fa alveol\u00e1ris h\u00e1msejtekben, mononukle\u00e1ris t\u00fcd\u0151 makrof\u00e1gokban \u00e9s endot\u00e9lsejtekben szintetiz\u00e1l\u00f3d\u00f3 P38 r\u00e9szt vesz a PF kialakul\u00e1s\u00e1nak t\u00f6bb szakasz\u00e1ban a gyullad\u00e1sos sejtek besziv\u00e1rg\u00e1s\u00e1nak, a fibroblasztok differenci\u00e1l\u00f3d\u00e1s\u00e1nak \u00e9s m\u00e1s folyamatok k\u00f6zvet\u00edt\u00e9s\u00e9vel. Az elm\u00falt \u00e9vek vonatkoz\u00f3 szakirodalm\u00e1nak olvas\u00e1sa sor\u00e1n kider\u00fclt, hogy a p38 \u00e1ltal k\u00f6zvet\u00edtett PF folyamata f\u0151k\u00e9nt a k\u00f6vetkez\u0151 pontokat foglalja mag\u00e1ban: el\u0151sz\u00f6r is, j\u00f3l ismert, hogy a TGF - \u03b2 kulcsmolekula a PF kialakul\u00e1s\u00e1ban. A p38 el\u0151seg\u00edti a TGF - \u03b2 szint\u00e9zis\u00e9t, epiteli\u00e1lis-mesenchym\u00e1lis \u00e1tmenetet (EMT) induk\u00e1l az alveol\u00e1ris epit\u00e9lsejtekben, \u00e9s a fibroblasztok aktiv\u00e1l\u00e1s\u00e1val r\u00e9szt vesz a PF kialakul\u00e1s\u00e1ban. M\u00e1sodszor, a p38 szab\u00e1lyozza az NF - \u03ba B feh\u00e9rje aktivit\u00e1s\u00e1t \u00e9s r\u00e9szt vesz a PF patogenezis\u00e9ben. Az NF - \u03ba B egy DNS-k\u00f6t\u0151 feh\u00e9rje, amely a Rel feh\u00e9rjecsal\u00e1d p65 \u00e9s p50 alegys\u00e9geib\u0151l \u00e1ll. Fontos transzkripci\u00f3s szab\u00e1lyoz\u00f3 az eukari\u00f3ta sejtekben, \u00e9s r\u00e9szt vehet az immunv\u00e1lasz szab\u00e1lyoz\u00e1s\u00e1ban a korai t\u00fcd\u0151alveol\u00e1ris gyullad\u00e1sban (PF) a gyullad\u00e1sos g\u00e9nek \u00e9s a TGF - \u03b2 g\u00e9nek \u00e1t\u00edr\u00e1s\u00e1nak el\u0151seg\u00edt\u00e9s\u00e9vel. Harmadszor, a p38 d\u00f6nt\u0151 szerepet j\u00e1tszik a fibroblasztok prolifer\u00e1ci\u00f3j\u00e1ban \u00e9s differenci\u00e1l\u00f3d\u00e1s\u00e1ban, valamint az extracellul\u00e1ris m\u00e1trix lerak\u00f3d\u00e1s\u00e1ban. A t\u00fal\u00e9l\u0151 myofibroblasztokban a p38 r\u00e9szt vesz a PF extracellul\u00e1ris m\u00e1trix lebont\u00e1s\u00e1ban az MMP-k mRNS-\u00e1t\u00edr\u00e1s\u00e1nak el\u0151seg\u00edt\u00e9s\u00e9vel.<\/p>\n

A fenti elemz\u00e9sb\u0151l l\u00e1that\u00f3, hogy a h\u00e1rom differenci\u00e1lisan expressz\u00e1lt feh\u00e9rje (TNF - \u03b1, MMP-9, p38) ebben a tanulm\u00e1nyban mind a TNF jel\u00e1tviteli \u00fatvonal upstream \u00e9s downstream csom\u00f3pontjain\u00e1l tal\u00e1lhat\u00f3, \u00e9s expresszi\u00f3juk szorosan \u00f6sszef\u00fcgg a PF megjelen\u00e9s\u00e9vel \u00e9s kialakul\u00e1s\u00e1val. A PF molekul\u00e1ris biol\u00f3giai v\u00e1ltoz\u00e1saiban r\u00e9szt vev\u0151 t\u00f6bb szempont \u00e9s jel\u00e1tviteli \u00fatvonal. Ebb\u0151l l\u00e1that\u00f3, hogy a hagyom\u00e1nyos k\u00ednai gy\u00f3gy\u00e1szati beavatkoz\u00e1s jellemz\u0151i a t\u00f6bb c\u00e9lpontot \u00e9s t\u00f6bb \u00fatvonalat \u00e9rint\u0151 hat\u00e1sok. Ugyanakkor a k\u00fcl\u00f6nb\u00f6z\u0151 \u00fatvonalak szorosan kapcsol\u00f3dnak egym\u00e1shoz, befoly\u00e1solj\u00e1k \u00e9s szab\u00e1lyozz\u00e1k egym\u00e1st. Ez t\u00fckr\u00f6zi a hagyom\u00e1nyos k\u00ednai orvosl\u00e1s hat\u00e1sainak \u00e1tfog\u00f3 koncepci\u00f3j\u00e1t is. Ebben a vizsg\u00e1latban azt tal\u00e1lt\u00e1k, hogy h\u00e1rom feh\u00e9rje (TNF - \u03b1, MMP-9, p38) v\u00e1ltoz\u00e1sa szignifik\u00e1nsan magas expresszi\u00f3t mutatott a modellcsoportban. A d\u00f3zis v\u00e1ltoz\u00e1s\u00e1val a feh\u00e9rjeexpresszi\u00f3 is gradiens v\u00e1ltoz\u00e1sokat \u00e9s koncentr\u00e1ci\u00f3f\u00fcgg\u00e9st mutatott. A k\u00eds\u00e9rleti r\u00e9sz nemcsak a k\u00e9s\u0151bbi kutat\u00e1saink ir\u00e1ny\u00e1t mutatta meg, hanem igazolta a kor\u00e1bbi h\u00e1l\u00f3zati farmakol\u00f3giai szekci\u00f3nkban v\u00e9gzett d\u00fas\u00edt\u00e1si elemz\u00e9s eredm\u00e9nyeinek tudom\u00e1nyos \u00e9rv\u00e9nyess\u00e9g\u00e9t is.<\/p>\n

\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"Az ebben a vizsg\u00e1latban r\u00e9szt vev\u0151 BHC-t els\u0151sorban a v\u00e9rkering\u00e9s el\u0151seg\u00edt\u00e9s\u00e9nek \u00e9s a v\u00e9r pang\u00e1s\u00e1nak megsz\u00fcntet\u00e9s\u00e9nek m\u00f3dszer\u00e9vel kezelik. A betegs\u00e9g ritkas\u00e1ga \u00e9s etiol\u00f3gi\u00e1j\u00e1nak \u00f6sszetetts\u00e9ge miatt jelenleg viszonylag kev\u00e9s naprak\u00e9sz epidemiol\u00f3giai adat \u00e1ll rendelkez\u00e9sre a PF-r\u0151l. Klinikai szempontb\u00f3l azonban el\u0151fordul\u00e1si ar\u00e1nya jelent\u0151sen emelkedik, ami az \u00faj coronav\u00edrus hossz\u00fa t\u00e1v\u00fa l\u00e9tez\u00e9s\u00e9nek, az ism\u00e9telt fert\u0151z\u00e9snek \u00e9s m\u00e1s t\u00e9nyez\u0151knek k\u00f6sz\u00f6nhet\u0151, amelyek ism\u00e9telten stimul\u00e1lj\u00e1k a t\u00fcd\u0151 interstitium\u00e1t. B\u00e1r jelent\u0151s el\u0151rel\u00e9p\u00e9s t\u00f6rt\u00e9nt a COVID-19 kezel\u00e9s\u00e9ben, m\u00e9g mindig sok megoldand\u00f3 probl\u00e9ma van az ilyen betegek hossz\u00fa t\u00e1v\u00fa k\u00f6vetkezm\u00e9nyeivel kapcsolatban, k\u00fcl\u00f6n\u00f6sen a PF kezel\u00e9s\u00e9ben. Mint ismeretes, a PF sz\u00e1mos t\u00fcd\u0151betegs\u00e9g, k\u00f6zt\u00fck a kr\u00f3nikus obstrukt\u00edv t\u00fcd\u0151betegs\u00e9g (COPD), a bronchiectasis \u00e9s az emphysema lass\u00fa progresszi\u00f3j\u00e1nak v\u00e9gs\u0151 eredm\u00e9nye. A PF korai szakasz\u00e1ban els\u0151sorban a qi stagn\u00e1l\u00e1sa \u00e9s a v\u00e9r pang\u00e1sa, a qi \u00e9s a v\u00e9r rossz kering\u00e9se, valamint a t\u00fcd\u0151 t\u00e1pl\u00e1l\u00e1s\u00e1nak hi\u00e1nya okozza. Ennek a st\u00e1diumnak a jellemz\u0151i a gyors kezdet, a r\u00f6vid ciklus \u00e9s a k\u00f6nny\u0171 kontroll. Ez\u00e9rt a korai kezel\u00e9snek a v\u00e9rkering\u00e9s el\u0151seg\u00edt\u00e9s\u00e9re \u00e9s a v\u00e9r pang\u00e1s\u00e1nak megsz\u00fcntet\u00e9s\u00e9re kell \u00f6sszpontos\u00edtania, kieg\u00e9sz\u00edtve a qi \u00e9s a yin t\u00e1pl\u00e1l\u00e1s\u00e1val; A PF v\u00e9gst\u00e1dium\u00e1ban l\u00e9v\u0151 betegekn\u00e9l a qi-hi\u00e1ny \u00e9s a l\u00e9gszomj, a gyenge felsz\u00edni v\u00e9delem \u00e9s az \u00e9rz\u00e9keny t\u00fcd\u0151 fog\u00e9konyabb a k\u00fcls\u0151 k\u00f3rokoz\u00f3k behatol\u00e1s\u00e1ra. Ennek a st\u00e1diumnak a jellemz\u0151i a betegs\u00e9g lass\u00fa progresszi\u00f3ja, hossz\u00fa ciklusa \u00e9s neh\u00e9z visszaford\u00edt\u00e1sa. Ebben a szakaszban a kezel\u00e9si strat\u00e9gi\u00e1nak els\u0151sorban a qi \u00e9s a yin t\u00e1pl\u00e1l\u00e1s\u00e1ra kell \u00f6sszpontos\u00edtania, kieg\u00e9sz\u00edtve a v\u00e9rkering\u00e9s el\u0151seg\u00edt\u00e9s\u00e9vel \u00e9s a v\u00e9r pang\u00e1s\u00e1nak megsz\u00fcntet\u00e9s\u00e9vel. Az ebben a vizsg\u00e1latban r\u00e9szt vev\u0151 \u00e1llatmodell megfelel a PF korai, akut kezdeti st\u00e1dium\u00e1nak, \u00e9s a kezel\u00e9snek els\u0151sorban a v\u00e9rkering\u00e9s el\u0151seg\u00edt\u00e9s\u00e9re \u00e9s a v\u00e9r pang\u00e1s\u00e1nak megsz\u00fcntet\u00e9s\u00e9re kell \u00f6sszpontos\u00edtania, ami \u00f6sszhangban van a BHC hat\u00e9konys\u00e1g\u00e1val. Ez k\u00f6zvetve felt\u00e1rja a BHC hat\u00e9konys\u00e1g\u00e1t \u00e9s tudom\u00e1nyoss\u00e1g\u00e1t, \u00e9s ir\u00e1nyt ad a kutat\u00f3csoportunk j\u00f6v\u0151beli kutat\u00e1saihoz is.<\/p>","protected":false},"excerpt":{"rendered":"

Exploring the potential mechanism of action of Bufei Huoxue Capsules in treating pulmonary fibrosis based on network pharmacology Pulmonary fibrosis (PF) is a chronic, irreversible interstitial lung disease characterized by the activation of lung fibroblasts into myofibroblasts and secretion of extracellular matrix. This disease is the end-stage manifestation of various lung diseases, where normal lung […]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"yoast_head":"\nExploring the potential mechanism of action of Bufei Huoxue Capsules in treating pulmonary fibrosis based on network pharmacology - China Chemical Manufacturer<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/longchangextracts.com\/hu\/bufei-huoxue-capsules\/\" \/>\n<meta property=\"og:locale\" content=\"hu_HU\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exploring the potential mechanism of action of Bufei Huoxue Capsules in treating pulmonary fibrosis based on network pharmacology - China Chemical Manufacturer\" \/>\n<meta property=\"og:description\" content=\"Exploring the potential mechanism of action of Bufei Huoxue Capsules in treating pulmonary fibrosis based on network pharmacology Pulmonary fibrosis (PF) is a chronic, irreversible interstitial lung disease characterized by the activation of lung fibroblasts into myofibroblasts and secretion of extracellular matrix. This disease is the end-stage manifestation of various lung diseases, where normal lung […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/longchangextracts.com\/hu\/bufei-huoxue-capsules\/\" \/>\n<meta property=\"og:site_name\" content=\"China Chemical Manufacturer\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-02T15:05:51+00:00\" \/>\n<meta name=\"author\" content=\"longcha9\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Szerz\u0151:\" \/>\n\t<meta name=\"twitter:data1\" content=\"longcha9\" \/>\n\t<meta name=\"twitter:label2\" content=\"Becs\u00fclt olvas\u00e1si id\u0151\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 perc\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/longchangextracts.com\/bufei-huoxue-capsules\/\",\"url\":\"https:\/\/longchangextracts.com\/bufei-huoxue-capsules\/\",\"name\":\"Exploring the potential mechanism of action of Bufei Huoxue Capsules in treating pulmonary fibrosis based on network pharmacology - China Chemical Manufacturer\",\"isPartOf\":{\"@id\":\"https:\/\/longchangextracts.com\/#website\"},\"datePublished\":\"2024-08-02T15:05:51+00:00\",\"dateModified\":\"2024-08-02T15:05:51+00:00\",\"author\":{\"@id\":\"https:\/\/longchangextracts.com\/#\/schema\/person\/80933ac6926ad63fea74ec33f8d04869\"},\"breadcrumb\":{\"@id\":\"https:\/\/longchangextracts.com\/bufei-huoxue-capsules\/#breadcrumb\"},\"inLanguage\":\"hu\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/longchangextracts.com\/bufei-huoxue-capsules\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/longchangextracts.com\/bufei-huoxue-capsules\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/longchangextracts.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exploring the potential mechanism of action of Bufei Huoxue Capsules in treating pulmonary fibrosis based on network pharmacology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/longchangextracts.com\/#website\",\"url\":\"https:\/\/longchangextracts.com\/\",\"name\":\"China Chemical Manufacturer\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/longchangextracts.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"hu\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/longchangextracts.com\/#\/schema\/person\/80933ac6926ad63fea74ec33f8d04869\",\"name\":\"longcha9\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"hu\",\"@id\":\"https:\/\/longchangextracts.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c1e84ee0759373263198c58e8f338f80?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c1e84ee0759373263198c58e8f338f80?s=96&d=mm&r=g\",\"caption\":\"longcha9\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A Bufei Huoxue kapszula lehets\u00e9ges hat\u00e1smechanizmus\u00e1nak felt\u00e1r\u00e1sa a t\u00fcd\u0151fibr\u00f3zis kezel\u00e9s\u00e9ben a h\u00e1l\u00f3zati farmakol\u00f3gia alapj\u00e1n - K\u00edna Chemical Manufacturer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/longchangextracts.com\/hu\/bufei-huoxue-capsules\/","og_locale":"hu_HU","og_type":"article","og_title":"Exploring the potential mechanism of action of Bufei Huoxue Capsules in treating pulmonary fibrosis based on network pharmacology - China Chemical Manufacturer","og_description":"Exploring the potential mechanism of action of Bufei Huoxue Capsules in treating pulmonary fibrosis based on network pharmacology Pulmonary fibrosis (PF) is a chronic, irreversible interstitial lung disease characterized by the activation of lung fibroblasts into myofibroblasts and secretion of extracellular matrix. This disease is the end-stage manifestation of various lung diseases, where normal lung […]","og_url":"https:\/\/longchangextracts.com\/hu\/bufei-huoxue-capsules\/","og_site_name":"China Chemical Manufacturer","article_published_time":"2024-08-02T15:05:51+00:00","author":"longcha9","twitter_card":"summary_large_image","twitter_misc":{"Szerz\u0151:":"longcha9","Becs\u00fclt olvas\u00e1si id\u0151":"9 perc"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/longchangextracts.com\/bufei-huoxue-capsules\/","url":"https:\/\/longchangextracts.com\/bufei-huoxue-capsules\/","name":"A Bufei Huoxue kapszula lehets\u00e9ges hat\u00e1smechanizmus\u00e1nak felt\u00e1r\u00e1sa a t\u00fcd\u0151fibr\u00f3zis kezel\u00e9s\u00e9ben a h\u00e1l\u00f3zati farmakol\u00f3gia alapj\u00e1n - K\u00edna Chemical Manufacturer","isPartOf":{"@id":"https:\/\/longchangextracts.com\/#website"},"datePublished":"2024-08-02T15:05:51+00:00","dateModified":"2024-08-02T15:05:51+00:00","author":{"@id":"https:\/\/longchangextracts.com\/#\/schema\/person\/80933ac6926ad63fea74ec33f8d04869"},"breadcrumb":{"@id":"https:\/\/longchangextracts.com\/bufei-huoxue-capsules\/#breadcrumb"},"inLanguage":"hu","potentialAction":[{"@type":"ReadAction","target":["https:\/\/longchangextracts.com\/bufei-huoxue-capsules\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/longchangextracts.com\/bufei-huoxue-capsules\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/longchangextracts.com\/"},{"@type":"ListItem","position":2,"name":"Exploring the potential mechanism of action of Bufei Huoxue Capsules in treating pulmonary fibrosis based on network pharmacology"}]},{"@type":"WebSite","@id":"https:\/\/longchangextracts.com\/#website","url":"https:\/\/longchangextracts.com\/","name":"K\u00edna Vegyi Gy\u00e1rt\u00f3","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/longchangextracts.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"hu"},{"@type":"Person","@id":"https:\/\/longchangextracts.com\/#\/schema\/person\/80933ac6926ad63fea74ec33f8d04869","name":"longcha9","image":{"@type":"ImageObject","inLanguage":"hu","@id":"https:\/\/longchangextracts.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c1e84ee0759373263198c58e8f338f80?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c1e84ee0759373263198c58e8f338f80?s=96&d=mm&r=g","caption":"longcha9"}}]}},"_links":{"self":[{"href":"https:\/\/longchangextracts.com\/hu\/wp-json\/wp\/v2\/posts\/3567"}],"collection":[{"href":"https:\/\/longchangextracts.com\/hu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/longchangextracts.com\/hu\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/longchangextracts.com\/hu\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/longchangextracts.com\/hu\/wp-json\/wp\/v2\/comments?post=3567"}],"version-history":[{"count":1,"href":"https:\/\/longchangextracts.com\/hu\/wp-json\/wp\/v2\/posts\/3567\/revisions"}],"predecessor-version":[{"id":3576,"href":"https:\/\/longchangextracts.com\/hu\/wp-json\/wp\/v2\/posts\/3567\/revisions\/3576"}],"wp:attachment":[{"href":"https:\/\/longchangextracts.com\/hu\/wp-json\/wp\/v2\/media?parent=3567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/longchangextracts.com\/hu\/wp-json\/wp\/v2\/categories?post=3567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/longchangextracts.com\/hu\/wp-json\/wp\/v2\/tags?post=3567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}